Chemotherapy for gynecologic cancers.
暂无分享,去创建一个
[1] L. Downs,et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. , 2011, Gynecologic oncology.
[2] M. Hatae,et al. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] H. Sommer,et al. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Saif,et al. Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review , 2010, Metal-based drugs.
[5] S. Grunberg,et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study , 2010, Supportive Care in Cancer.
[6] M. Kris,et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] A. Iasonos,et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. , 2010, Gynecologic oncology.
[8] M. Chamberlain. Neurotoxicity of Cancer Treatment , 2010, Current oncology reports.
[9] T. Jobo,et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.
[10] D. Cella,et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Sudhakar Tummala,et al. NCCN task force report: management of neuropathy in cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[12] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[13] Robert S Mannel,et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] W. Voigt,et al. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. , 2009, European journal of cancer.
[15] L. Asmar,et al. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Cella,et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. , 2009, Gynecologic oncology.
[17] R. Berkowitz,et al. Current management of gestational trophoblastic diseases. , 2009, Gynecologic oncology.
[18] P. Sabbatini,et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. , 2009, Gynecologic oncology.
[19] B. Monk,et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] S. Grunberg,et al. Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes. , 2009, Clinical journal of oncology nursing.
[21] G. Kenter,et al. EORTC-GcG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA) , 2008 .
[22] A. Sharifi,et al. Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia , 2008, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[23] R. Mannel,et al. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. , 2008, Gynecologic oncology.
[24] P. Schwartz. What is the role of neoadjuvant chemotherapy in the management of ovarian cancer? , 2008, Oncology.
[25] N. Sebire,et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] M. Deavers,et al. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. , 2008, Gynecologic oncology.
[27] P. Hesketh. Chemotherapy-induced nausea and vomiting. , 2008, The New England journal of medicine.
[28] P. Rose,et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. , 2008, Gynecologic oncology.
[29] A. Psyrri,et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. , 2008, Gynecologic oncology.
[30] D. Katsaros,et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Michael W Sill,et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Howard Mackey,et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] L. Roman,et al. Phase II Clinical Trial of Docetaxel in Refractory Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study , 2007, American journal of clinical oncology.
[34] H. Andersson,et al. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel— long- term follow- up , 2007, International Journal of Gynecologic Cancer.
[35] D. Mutch,et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] J. Thigpen,et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] D. Alberts,et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). , 2007, Gynecologic oncology.
[38] J. Fine,et al. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. , 2007, Gynecologic oncology.
[39] J. Desai,et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas , 2007, Cancer.
[40] L. Einhorn,et al. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer , 2007, Supportive Care in Cancer.
[41] C. Thomssen,et al. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. , 2007, Gynecologic oncology.
[42] A. Berchuck,et al. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer , 2007, International Journal of Clinical Oncology.
[43] A. Oza,et al. Intraperitoneal chemotherapy in the first‐line treatment of women with stage III epithelial ovarian cancer , 2007, Cancer.
[44] T. Powles,et al. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia , 2007, British Journal of Cancer.
[45] B. Monk,et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] E. Esteban,et al. Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas , 2007, Cancer Chemotherapy and Pharmacology.
[47] S. Wilhelm,et al. Prevention of Postoperative Nausea and Vomiting , 2007, The Annals of pharmacotherapy.
[48] E. Eisenhauer,et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Jeffrey Bell,et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. , 2006, Gynecologic oncology.
[50] D. Bodurka,et al. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. , 2006, Gynecologic oncology.
[51] P. Rose,et al. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. , 2006, Gynecologic oncology.
[52] J. Soper. Gestational trophoblastic disease. , 2006, Obstetrics and gynecology.
[53] A. Schott,et al. What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence. , 2006, Gynecologic oncology.
[54] B. Dörken,et al. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. , 2006, Gynecologic oncology.
[55] S. Waggoner,et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. , 2006, Gynecologic oncology.
[56] G. Lyman,et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients , 2006, Cancer.
[57] Joan L. Walker,et al. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] F. Lombardo,et al. Extravasation of chemotherapeutic agents: prevention and treatment. , 2006, Seminars in oncology.
[59] Gianni Tognoni,et al. Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials , 2006, JAMA.
[60] B. Monk,et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] J. McAlpine,et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. , 2005, Gynecologic oncology.
[62] D. Miller,et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] C. Aghajanian,et al. Temozolomide in uterine leiomyosarcomas. , 2005, Gynecologic oncology.
[64] A. Berger,et al. Practical management of chemotherapy-induced nausea and vomiting. , 2005, Oncology.
[65] G. Sutton,et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. , 2005, Gynecologic oncology.
[66] B. Monk,et al. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. , 2005, Gynecologic oncology.
[67] G. Sutton,et al. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. , 2005, Gynecologic oncology.
[68] R. Burger,et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] G. Matsunaga,et al. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. , 2004, Gynecologic oncology.
[70] D. Cella,et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] R. Bentley,et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[72] M. Dimopoulos,et al. Hormonal Therapy with Letrozole for Relapsed Epithelial Ovarian Cancer , 2004, Oncology.
[73] E. Eisenhauer,et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers – a study of the National Cancer Institute of Canada Clinical Trials Group , 2004, International Journal of Gynecologic Cancer.
[74] J. Lucci,et al. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. , 2004, Gynecologic oncology.
[75] U. Matulonis,et al. Phase II trial of anastrozole in women with asymptomatic müllerian cancer. , 2003, Gynecologic oncology.
[76] F. Roila,et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] J. Lea,et al. Management of low-risk gestational trophoblastic neoplasia in indigent women. , 2003, The Journal of reproductive medicine.
[78] Robert S Mannel,et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] R. Broaddus,et al. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets. , 2003, Gynecologic oncology.
[80] M. Markman,et al. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. , 2003, Gynecologic oncology.
[81] M. Morgan,et al. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] Gary H Lyman,et al. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. , 2003, Journal of the National Comprehensive Cancer Network : JNCCN.
[83] G. Mor,et al. Low-grade endometrial stromal sarcoma: hormonal aspects. , 2003, Gynecologic oncology.
[84] V. Torri,et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial , 2003, The Lancet.
[85] N. Colombo,et al. What have we learned from ICON1 and ACTION? , 2003, International Journal of Gynecologic Cancer.
[86] M. Morgan,et al. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. , 2003, Gynecologic oncology.
[87] Roger B. Lee,et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. , 2003, Gynecologic oncology.
[88] F. Amant,et al. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. , 2003, Gynecologic oncology.
[89] M. Piccart,et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[90] P. Rose,et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. , 2003, Gynecologic oncology.
[91] D. Bodurka,et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] L. Pirtoli,et al. Adjuvant Epirubicin With or Without Ifosfamide for Adult Soft-Tissue Sarcoma , 2002, American journal of clinical oncology.
[93] H. Gabra,et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[94] E. Venkatraman,et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] J. Sorosky,et al. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] M. Johnston,et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. , 2002, Gynecologic oncology.
[97] G. Rustin,et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] E. Kohorn. Is lack of response to single-agent chemotherapy in gestational trophoblastic disease associated with dose scheduling or chemotherapy resistance? , 2002, Gynecologic oncology.
[99] C. Haie-meder,et al. Results of conservative treatment in epithelial ovarian carcinoma , 2001, Cancer.
[100] S. Wilailak,et al. Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer , 2001, Anti-cancer drugs.
[101] H. Hansen,et al. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. , 2001, Gynecologic oncology.
[102] P. Zola,et al. Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. , 2001, European journal of cancer.
[103] J. Kwon,et al. Weekly intravenous methotrexate with folinic acid for nonmetastatic gestational trophoblastic neoplasia. , 2001, Gynecologic oncology.
[104] D Guthrie,et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[105] L. Muderspach,et al. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 2001, Gynecologic oncology.
[106] B N Bundy,et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[107] M. Brady,et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] E. Kohorn. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assessment , 2000, International Journal of Gynecologic Cancer.
[109] G. Sutton,et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. , 2000, Gynecologic oncology.
[110] L. Elting,et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] Joan L. Walker,et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. , 2000, Gynecologic oncology.
[112] J. Blay,et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] T. Herzog,et al. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. , 2000, Gynecologic oncology.
[114] R. Talamini,et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[115] P. Grigsby,et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] C. Dunton,et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] R. Alvarez,et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[118] B N Bundy,et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[119] B N Bundy,et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. , 1999, The New England journal of medicine.
[120] B N Bundy,et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. , 1999, The New England journal of medicine.
[121] P J Eifel,et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. , 1999, The New England journal of medicine.
[122] B. Monk,et al. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. , 1999, Gynecologic oncology.
[123] A. Benson,et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[124] F. Sopracordevole,et al. Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma. , 1998, Gynecologic oncology.
[125] S. Kim,et al. Effects of multiagent chemotherapy and independent risk factors in the treatment of high‐risk GTT —25 years experiences of KRI‐TRD , 1998, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[126] E. Atkinson,et al. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] J A Blessing,et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[128] M. Piccart,et al. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview. , 1997, European journal of cancer.
[129] R. Winn,et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix , 1997, Anti-cancer drugs.
[130] E S Newlands,et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[131] A Gordon,et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[132] L J Liang,et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[133] C. Verschraegen,et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[134] G. Sutton,et al. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study. , 1996, Gynecologic oncology.
[135] S. Lentz,et al. A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. , 1996, American journal of clinical oncology.
[136] G. Sutton,et al. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. , 1996, Gynecologic oncology.
[137] D. Mutch,et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. , 1996, Gynecologic oncology.
[138] K. Hatch,et al. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. , 1996, Gynecologic oncology.
[139] S. Nicosia,et al. Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: a phase II study. , 1996, Gynecologic oncology.
[140] W. Mcguire,et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[141] M. Brady,et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[142] E. Partridge,et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.
[143] O. Garrone,et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[144] M. Ratain,et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.
[145] G. Sutton,et al. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study. , 1994, Gynecologic oncology.
[146] P. Hérait,et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. , 1994, Journal of the National Cancer Institute.
[147] J. Kavanagh,et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. , 1993, Gynecologic oncology.
[148] G. Sutton,et al. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. , 1993, American journal of obstetrics and gynecology.
[149] I. Vergote,et al. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. , 1992 .
[150] Portal Hypertension: Clinical and Physiological Aspects , 1992, Annals of Internal Medicine.
[151] M. Markman,et al. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[152] G. Sutton,et al. Phase II trial of ifosfamide and mesna in leiomyosarcoma ofthe uterus: A Gynecologic Oncology Group study , 1992 .
[153] S. Rubin,et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[154] R. Diasio,et al. Severe 5‐fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome , 1991, Cancer.
[155] S. Rubin,et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[156] D. Alberts,et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. , 1990, Gynecologic oncology.
[157] S. Ellenberg,et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials , 1990, The New England journal of medicine.
[158] R. O’Toole,et al. Carboplatin therapy in advanced endometrial cancer , 1990, Obstetrics and gynecology.
[159] J. Droz,et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. , 1990, The New England journal of medicine.
[160] P. O'Brien,et al. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. , 1990, American journal of obstetrics and gynecology.
[161] G. Sutton,et al. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix , 1989, Investigational New Drugs.
[162] C. Redman,et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. , 1989, British Journal of Cancer.
[163] G. Marks,et al. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[164] F. Landoni,et al. EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). , 1988, Gynecologic oncology.
[165] M. Pasmantier,et al. Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients. , 1985, Cancer treatment reports.
[166] S. Vogl,et al. Adriamycin and cis-diamminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma. , 1984, Gynecologic oncology.
[167] R. Zaino,et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas , 1983, Cancer.
[168] J. Herson,et al. Cisplatin Chemotherapy for Disseminated Endometrial Cancer , 1982, Obstetrics and gynecology.
[169] L. Lagasse,et al. Cis‐platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase ii study of the gynecologic oncology group , 1981, Cancer.
[170] C. Cohen,et al. Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammine platinum (II) after intensive prior therapy. , 1980, Gynecologic oncology.
[171] G. Ross,et al. Primary chemotherapy for nonmetastatic gestational trophoblastic neoplasms. , 1967, American journal of obstetrics and gynecology.
[172] W. Gradishar,et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[173] S. Groshen,et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[174] M. Parmar,et al. Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[175] G. Giaccone,et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[176] J. Thigpen,et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[177] R. Schilder,et al. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. , 2005, Gynecologic oncology.
[178] P. Coyne,et al. Symptom management , 2005, Bone Marrow Transplantation.
[179] R. Souhami,et al. A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix , 2004, Cancer Chemotherapy and Pharmacology.
[180] J. Fiorica,et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.
[181] P. Disaia,et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. , 2003, Gynecologic oncology.
[182] P. Rose,et al. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. , 2003, Gynecologic oncology.
[183] S. Groshen,et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy , 2001, The Pharmacogenomics Journal.
[184] D. Mutch,et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[185] V. D’addario,et al. Leuprolide acetate as a salvage-therapy in relapsed epithelial ovarian cancer. , 1996, European journal of gynaecological oncology.
[186] J. Vermorken,et al. Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. , 1994, European journal of cancer.
[187] Francesco Maneschi,et al. Surgical pathological staging of endometrial carcinoma and results of treatment. , 1992, European journal of gynaecological oncology.
[188] R. Diasio,et al. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. , 1988, The Journal of clinical investigation.
[189] J. Thigpen,et al. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. , 1979, Cancer treatment reports.
[190] U. Matulonis,et al. Food , drug , insect sting allergy , and anaphylaxis Hypersensitivity reactions to chemotherapy : Outcomes and safety of rapid desensitization in 413 cases , 2022 .
[191] P. Vasey,et al. © 2001 Cancer Research Campaign , 2022 .